Dublin, Dec. 14, 2022 (GLOBE NEWSWIRE) -- The "Deep Brain Stimulators (DBS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive information about the Deep Brain Stimulators (DBS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
A DBS is a device that is comprised of a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation through surgically-implanted electrodes to specific targets in the brain.
Scope
- Extensive coverage of the Deep Brain Stimulators (DBS) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Deep Brain Stimulators (DBS) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment/industry
Reasons to Buy
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Deep Brain Stimulators (DBS) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Deep Brain Stimulators (DBS) Overview
3 Products under Development
3.1 Deep Brain Stimulators (DBS) - Pipeline Products by Stage of Development
3.2 Deep Brain Stimulators (DBS) - Pipeline Products by Territory
3.3 Deep Brain Stimulators (DBS) - Pipeline Products by Regulatory Path
3.4 Deep Brain Stimulators (DBS) - Pipeline Products by Estimated Approval Date
3.5 Deep Brain Stimulators (DBS) - Ongoing Clinical Trials
4 Deep Brain Stimulators (DBS) - Pipeline Products under Development by Companies
4.1 Deep Brain Stimulators (DBS) Companies - Pipeline Products by Stage of Development
4.2 Deep Brain Stimulators (DBS) - Pipeline Products by Stage of Development
5 Deep Brain Stimulators (DBS) Companies and Product Overview
6 Deep Brain Stimulators (DBS)- Recent Developments
6.1 Aug 23, 2022: Medtronic reports first quarter fiscal 2023 financial results
6.2 Aug 23, 2022: NeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
6.3 Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule
6.4 Aug 11, 2022: NeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business Update
6.5 Jul 21, 2022: NeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022
6.6 Jul 12, 2022: Aspire & USF Pass $10M in ticket & donation revenue
6.7 Jun 27, 2022: Medtronic Board appoints Lidia Fonseca as a new director
6.8 Jun 22, 2022: BrainsWay to Present at the H.C. Wainwright 1st Annual Mental Health Conference
6.9 May 27, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results
6.10 May 26, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase
6.11 May 19, 2022: U of I trustees appoint new chancellor at UIS
6.12 May 13, 2022: NeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare Conference
6.13 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022
6.14 Apr 27, 2022: BrainsWay to Report First Quarter Financial Results on May 11, 2022
6.15 Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022
6.16 Apr 14, 2022: Leading Quantum Scientist Prineha Narang Appointed to Named Professorship at UCLA
6.17 Mar 28, 2022: BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy
6.18 Mar 10, 2022: NeuroPace Reports Fourth Quarter & Full Year 2021 Financial Results
6.19 Feb 28, 2022: BrainsWay to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022
6.20 Jan 26, 2022: BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board
6.21 Jan 04, 2022: Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference
6.22 Nov 08, 2021: Boston Scientific Announces Upcoming Conference Schedule
6.23 Nov 03, 2021: BrainsWay to Report Third Quarter 2021 Financial Results on November 17, 2021
6.24 Oct 27, 2021: Boston Scientific Announces Results For Third Quarter 2021
6.25 Oct 12, 2021: BrainsWay Announces Prominent Addition to Scientific Advisory Board
6.26 Sep 09, 2021: BrainsWay to Participate in Two Upcoming Investor Conferences
6.27 Sep 09, 2021: Boston Scientific Announces 2021 Investor Day Meeting
7 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/yv2ysy
